Organon & Co | OGN - Assets


Organon & Co reported $13B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Celltrion KRW 759.44B 20.32T Dec/2025
Cspc Pharmaceutical CNY 46.7B 695.56M Dec/2025
Deva Holding AS TRY 12.93B 1.83B Sep/2023
Dianthus Therapeutics USD 1.25B 715.96M Mar/2026
Divis Laboratories Ltd INR 200.33B 18.82B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Kangmei Pharma CNY 13.31B 375.64M Mar/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Laboratorios Farma EUR 799.88M 99.95M Dec/2023
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 63.57M 2.83M Dec/2025
Merck USD 128.68B 8.18B Mar/2026
Neuren Pharmaceuticals AUD 342.86M 11.61M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Organigram Holdings CAD 530.67M 31.54M Dec/2025
Organon & Co USD 13B 129M Mar/2026
Ovoca Bio EUR 1.66M 9.75M Jun/2025
Pharma Mar EUR 385.26M 9.82M Mar/2026
Qiagen NV USD 6.3B 257.54M Dec/2025
Sartorius EUR 9.87B 154.9M Mar/2026
Sino Biopharmaceutical CNY 74.89B 9.49B Jun/2025
Tilray USD 2.1B 15.95M Sep/2025
Zealand Pharma A/S 15.95B 848.45M Dec/2025